Memscreen, app helps generalists detect: This article explores the topic in depth.
Moreover,
Memscreen. Therefore, app helps generalists detect:
A short, standardized test and achievable in a few minutes in the office: here is the promise of Memscreen, an application developed to help generalists in the detection of light cognitive disorders and the first signs of Alzheimer’s disease.
Developed at the Cognitive Neurology Center of the Lariboisière Hospital (AP-HP). Furthermore, this solution, launched in 2023, presents itself as a simple and fast first line test (less than 5 minutes), usable in consultation. However, Available for free on smartphone, tablet or computer, the application immediately provides an interpretable score by the practitioner. Nevertheless, “We do not pretend to make an etiological diagnosis. Meanwhile, It is rather an aid to the general practitioners. Therefore, it gives them an alert signal to think about orient their patients towards a specialized consultation if necessary ”specifies Professor Julien Dumurgier, neurologist at the origin of the memscreen, app helps generalists detect project.
The main advantage, the test is easily integrated into a general medicine consultation sequence, which makes it usable routine. However, “Concretely. However, the doctor can write a prescription, make a address for the memory consultation or even prescribe an MRI while the patient is taking the test”, underlines the neurologist. Unlike other tests such as MMSE (mini-moderate examination. editor’s note), more time-consuming, the Memscreen solution allows the doctor to continue his tasks, by evaluating his patient.
With approximately 1.2 million people affected by Alzheimer’s disease in France. and nearly 225,000 new cases diagnosed each year, the stake of location is major. “Alzheimer’s disease remains diagnosed at a fairly advanced stage in France because the warning signs are ignored or poorly identified. Patients only arrive in memory consultation only to an advanced stage of the disease. which limits the possibilities of management ”insists Professor Dumurgier.
With the recent memscreen, app helps generalists detect leccanab permission in Europe – the first immunotherapy targeting the amyloid at the early stage of the disease -. patient care could cross a CAP. “We are now awaiting the ANSM’s decision, probably for early access at first. But it’s really time to mobilize because many patients could benefit from it ”rejoices the neurologist.
Memscreen. app helps generalists detect – Memscreen, app helps generalists detect
Already 10,000 tests carried out
A double validation study confirmed the performance of the Memscreen solution in the detection of cognitive disorders. In Great Britain. a cohort of more than 2,000 elderly people passed the test as part of a large study on aging. Result: Memscreen has better discriminated against early cognitive disorders than the classic test (MMSE). In France. the app was compared to a memory test used in specialized consultation in the event of a cognitive complaint. Again, the tool has demonstrated its great sensitivity to identify the first memscreen, app helps generalists detect signs of light cognitive disorders.
To date, more than 1,500 accounts have been created and more than 10,000 tests carried out. For its development, the application benefited from funding from the Bettencourt Foundation and the Alzheimer Foundation. “One of our objectives would obviously be that doctors can quote the performance of cognitive tests. this could encourage them to do more”imagine the neurologist. Already available in French and English, the application should soon be developed in other languages.
Further reading: Babies can feel it before understanding it – Women’s health: coffee, an anti-aging ally? – Pitch: Vipali, a health prevention application – Coffee: an elixir of youth? Harvard is studying his impact on women – Strong suspicion of Aboriginal case from Chikungunya in Montoison (Drôme): PO.
